Donald G. Vidt, MD Consultant, Department of Nephrology and Hypertension, Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A101, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195
Dr. Vidt has indicated that he has received grant or research support from the Searle, Astra-Zeneca, and Novartis companies and serves on the speakers' bureaus of the Astra-Zeneca, Merck, Novartis, and Solvay companies, all of which make antihypertensive agents.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a large, randomized double-blind study comparing four antihypertensive agents (chlorthalidone, doxazosin, amlodipine, and lisinopril) in hypertensive patients older than 55 years. The doxazosin arm was terminated early, when the trial's safety and monitoring board noted a twofold higher incidence of congestive heart failure in patients receiving doxazosin than in those receiving chlorthalidone (8.13% vs 4.45% at 4 years, P < .001).